Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne (TEENA)

• Severity of acne [ Time Frame: at baseline and after 12 weeks of treatment ] [ Designated as safety issue: No ]
  efficacy is assessed by change in severity of acne according to the Leeds revised acne grading system
  
  

• local skin irritations [ Time Frame: over 12 weeks ] [ Designated as safety issue: Yes ]
  
• treatment adherence [ Time Frame: at final examination after 12 weeks of treatment ] [ Designated as safety issue: No ]
  treatment adherence is assessed by the physician using a mini-questionnaire recently published by the international acne expert group "Global Alliance to Improve Outcomes in Acne"
  
  

Drug: 0.1% adapalene/ 2.5% benzoyl peroxide
topical application, once per day
Other Name: Epiduo

The objective of this observational study is to assess the efficacy of Epiduo and patient adherence under daily clinical practice conditions in adults and adolescents (12 to 20 years) with moderate inflammatory acne using this drug first time in topical monotherapy. This non-interventional trial will include a larger population of teenaged acne patients in order to establish the practical contribution of a new mini-questionnaire to the evaluation of adherence for the physician in the daily clinical practice in general and in young adults topically treated with Epiduo in particular. In addition safety and local tolerability profile of Epiduo are to be assessed under marketed conditions.